Perfusion Medical is commercializing PEG-20k, a drug for the restoration of tissue perfusion developed by researchers at VCU with $12M in Army funding. PEG-20k is a promising potential therapy for patients affected by shock with potential annual sales of $4B and is referred to as a “game-changer” by independent doctors. In large animal trials, the patent-protected IV solution worked 10 to 20 times better than current standards of care.